Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

1134153

USP

Cilostazol

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-chinolinon, OPC 13013, OPC 21, Pletaal

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C20H27N5O2
CAS-Nummer:
73963-72-1
Molekulargewicht:
369.46
MDL-Nummer:
MFCD00866780
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329749401
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

cilostazol

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChIKey

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Angaben zum Gen

human ... PDE3A(5139)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Anwendung

Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1134164

Cilostazol-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1134175

Cilostazol-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1134186

Cilostazol-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

PHR1503

Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1653

Cilostazol-verwandte Verbindung B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1676

Cilostazol-verwandte Verbindung C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2855

Cilostazol-verwandte Verbindung A, pharmaceutical secondary standard, certified reference material

Piktogramme

Health hazard
GHS08

Signalwort

Warning

H-Sätze

H361d

Gefahreneinstufungen

Repr. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Jae-Sik Jang et al.
Cardiology, 122(3), 133-143 (2012-07-27)
To evaluate the impact of cilostazol on the angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) with stents and treated with aspirin and thienopyridine. A total of 11 randomized controlled trials including 8,525 patients comparing triple antiplatelet
Deng-Feng Geng et al.
Cardiology, 122(3), 148-157 (2012-07-27)
Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting. We performed a meta-analysis of all relevant randomized controlled trials (RCTs) to investigate the effect of TAT versus dual
S Takahashi et al.
Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with
Courtney J Warner et al.
Journal of vascular surgery, 59(6), 1607-1614 (2014-01-29)
Although cilostazol is commonly used as an adjunct after peripheral vascular interventions, its efficacy remains uncertain. We assessed the effect of cilostazol on outcomes after peripheral vascular interventions using meta-analytic techniques. We searched MEDLINE (1946-2012), Cochrane CENTRAL (1996-2012), and trial
Sayuri N Friedland et al.
The American journal of cardiology, 109(10), 1397-1404 (2012-03-03)
Cilostazol is a generic drug with antiplatelet and antiproliferative effects. It is unclear whether adding cilostazol to standard dual antiplatelet therapy (aspirin and clopidogrel) after percutaneous coronary intervention reduces restenosis and improves the outcomes. We, therefore, conducted a systematic review
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.